LUND, SWEDEN--(Marketwire - April 06, 2010) -
The Board of Directors of Active Biotech AB (publ) has issued a notice to the Annual General Meeting, which is to take place at 5 p.m. on Thursday, May 6, 2010, at the Company’s premises at Scheelevagen gen 22 in Lund, Sweden.
Please see the attached notification, which is being published within short In Svenska Dagbladet and Post- och Inrikes Tidningar.
Lund, April 6, 2010
ACTIVE BIOTECH AB (PUBL)
THE BOARD OF DIRECTORS
About Active Biotech
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with R&D focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phases are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, and ANYARA for use in cancer targeted therapy, primarily renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDexTM for RA.
Active Biotech AB P.O. Box 724, SE-220 07 Lund Sweden Tel: +46 (0)46-19 20 00 Fax: +46 (0)46-19 11 00
Active Biotech is obligated to publish the information contained in this press release in accordance with the Swedish Securities Market Act. This information was provided to the media for publication on April 6, 2010, at 8:30 a.m.
[HUG#1400601]
Active Biotech AB Notice of Annual General Meeting of Shareholders: http://hugin.info/1002/R/1400601/355855.pdf
